<SEC-DOCUMENT>0001062993-17-005253.txt : 20171214
<SEC-HEADER>0001062993-17-005253.hdr.sgml : 20171214
<ACCEPTANCE-DATETIME>20171214154435
ACCESSION NUMBER:		0001062993-17-005253
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171214
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171214
DATE AS OF CHANGE:		20171214

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lexaria Bioscience Corp.
		CENTRAL INDEX KEY:			0001348362
		STANDARD INDUSTRIAL CLASSIFICATION:	METAL MINING [1000]
		IRS NUMBER:				202000871
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52138
		FILM NUMBER:		171256105

	BUSINESS ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4
		BUSINESS PHONE:		250-765-6424

	MAIL ADDRESS:	
		STREET 1:		156 VALLEYVIEW ROAD
		CITY:			KELOWNA
		STATE:			A1
		ZIP:			V1X 3M4

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXARIA CORP.
		DATE OF NAME CHANGE:	20080229

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lexaria Corp.
		DATE OF NAME CHANGE:	20051229
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Form 8-K - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=center><B><FONT size=5>UNITED STATES</FONT></B><BR><B><FONT
size=5>SECURITIES AND EXCHANGE COMMISSION</FONT></B><BR>Washington, D.C. 20549
</P>
<P align=center><B><FONT size=5>FORM 8-K </FONT></B></P>
<P align=center><B>CURRENT REPORT </B></P>
<P align=center>Pursuant to Section 13 OR 15(d) of the Securities Exchange Act
of 1934 </P>
<P align=center>Date of Report (Date of earliest event reported) <B><U>December
14, 2017</U></B></P>
<P align=center><B><U><FONT size=5>LEXARIA BIOSCIENCE CORP.</FONT></U></B><B>
</B><BR>(Exact name of registrant as specified in its charter) </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=center><B><U>Nevada </U></B></TD>
    <TD align=center width="33%"><B><U>000-52138 </U></B></TD>
  <TD align=center width="33%"><B><U>20-2000871 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>(State or other jurisdiction of </TD>
    <TD align=center width="33%">(Commission File Number) </TD>
  <TD align=center width="33%">(IRS Employer </TD>
  </TR>
  <TR vAlign=top>
    <TD align=center>incorporation) </TD>
    <TD align=center width="33%">&nbsp; </TD>
  <TD align=center width="33%">Identification No.) </TD>
  </TR></TABLE><BR>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD width="50%" align=center><B><U>156 Valleyview Road, Kelowna, BC Canada </U></B></TD>
  <TD align=center width="50%" ><B><U>V1X 3M4 </U></B></TD>
  </TR>
  <TR vAlign=top>
    <TD width="50%" align=center>(Address of principal executive offices) </TD>
  <TD align=center width="50%" >(Zip Code) </TD>
  </TR></TABLE>
<P align=center>Registrant&#146;s telephone number, including area code<B><U>(250) 765-6424</U></B><B> </B></P>
<P align=center><B><U>N/A</U></B><B> </B><BR>(Former name or former address, if
changed since last report.) <BR></P>
<P align=justify>Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</P>
<P align=justify>[&nbsp;&nbsp; ]&nbsp; Written communications pursuant to Rule
425 under the Securities Act (17 CFR 230.425)<BR>[&nbsp;&nbsp; ]&nbsp;
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)<BR>
[&nbsp;&nbsp; ]&nbsp; Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR>
[&nbsp;&nbsp;
]&nbsp; Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))<BR>
</P>
<P align=justify>Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of
this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b -2
of this chapter). </P>
<P align=right>Emerging growth company [&nbsp;&nbsp; ]</P>
<P align=justify>If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to
Section 13(a) of the Exchange Act. [&nbsp;&nbsp; ]</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=center>- 2 - </P>
<P align=justify><B>Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Regulation FD Disclosure </B></P>
<P align=justify>A copy of the news release announcing that the US Patent and
  Trademark Office has granted Lexaria patent number 9,839,612 B2 for the use of
  DehydraTECH<SUP>TM </SUP>technology as a delivery platform for a wide variety of
  Active Pharmaceutical Ingredients (&#147;APIs&#148;) including all cannabinoids including
  THC; fat soluble vitamins; non-steroidal anti-inflammatory pain
  medications (&#147;NSAIDs&#148;); and nicotine is filed as exhibit 99.1 to this current
  report and is hereby incorporated by reference.</P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD align=left><B>Item 9.01</B> </TD>
    <TD align=left width="90%" ><B>Financial Statements and
      Exhibits</B> </TD></TR>
  <TR>
    <TD align=left >&nbsp;</TD>
    <TD align=left width="90%"  >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left bgColor=#eeeeee><a href="exhibit99-1.htm">99.1 </a></TD>
    <TD align=left width="90%" bgColor=#eeeeee ><a href="exhibit99-1.htm">Press Release
      dated December 13, 2017 </a></TD>
  </TR></TABLE>
<P align=center><B>SIGNATURES </B></P>
<P align=justify>Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P>
<P align=justify><B>LEXARIA BIOSCIENCE CORP.</B> </P>
<TABLE
style="BORDER-COLOR: black; FONT-SIZE: 10pt; BORDER-COLLAPSE: collapse; "
cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=top>
    <TD style="BORDER-BOTTOM: #000000 1px solid" align=left><I>/s/ Chris
      Bunka</I> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left><B>Chris Bunka</B> </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR>
  <TR vAlign=top>
    <TD align=left>CEO, Principal Executive Officer </TD>
    <TD align=left width="50%" >&nbsp;</TD></TR></TABLE>
<P align=justify>Date:&nbsp;&nbsp;&nbsp; December 14, 2017</P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
   <TITLE>Lexaria Bioscience Corp. - Exhibit 99.1 - Filed by newsfilecorp.com</TITLE>
</HEAD>
<BODY style="font-size:10pt;">
<HR noshade align="center" width=100% size=3 color="black">
<A name=page_1></A>
<P align=right><B>Exhibit 99.1 </B></P>
<P align=center><B>Lexaria Bioscience Receives U.S. Patent Award for its
DehydraTECH</B><B><SUP>TM</SUP></B><B> Delivery of THC, NSAIDs, Nicotine and
Vitamins. </B></P>
<P align=justify>Kelowna, British Columbia &#150; December 13, 2017 &#150; Lexaria
Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) (the &#147;Company&#148; or &#147;Lexaria&#148;) a drug
delivery platform innovator, announces the United States Patent and Trademark
Office (&#147;USPTO&#148;) has granted patent number 9,839,612 B2 for the use of
DehydraTECH<SUP>TM</SUP> technology as a delivery platform for a wide variety of
Active Pharmaceutical Ingredients (&#147;APIs&#148;) including all cannabinoids including
THC; fat soluble vitamins; non-steroidal anti-inflammatory pain medications
(&#147;NSAIDs&#148;); and nicotine.</P>
<P align=justify>This granted patent completes the patent allowance process that
was announced on October 31, 2017, and this patent grant is now final. The title
of the granted patent is &#147;Food and Beverage Compositions Infused With Lipophilic
Active Agents and Methods of Use Thereof&#148;. This issued patent protects Lexaria&#146;s
intellectual property (&#147;IP&#148;) for the DehydraTECH<SUP>TM</SUP> delivery of all
the active substances noted via nearly any kind of processed food or beverage as
well as capsules and pills. </P>
<P align=justify>In one aspect a method of treating a condition is provided
wherein a cannabinoid is used to treat conditions selected from the group
consisting of cardiac diseases such as heart disease, ischemic infarcts, and
cardiometabolic disorders, neurological diseases such as Alzheimer&#146;s disease,
Parkinson&#146;s disease, schizophrenia, and Human Immunodeficiency Virus (HIV)
dementia; obesity; metabolic disorders such as insulin related deficiencies and
lipid profiles, hepatic diseases, diabetes, and appetite disorders; cancer
chemotherapy, benign prostatic hypertrophy; irritable bowel syndrome, biliary
diseases; ovarian disorders; marijuana abuse; and alcohol, opioid, nicotine or
cocaine addiction. </P>
<P align=justify>Lexaria also continues to advance all of its additional patent
applications in various countries as it levers patent success in the USA. For
example, some of the Company&#146;s patent applications have recently entered the
active patent investigation phase in China, the European Union, and in Canada.
</P>
<P align=justify>&#147;Lexaria has now locked-up the IP for its next-generation drug
delivery system&#148; said Chief Executive Officer Chris Bunka. &#147;This
ground-breaking, patented IP builds a foundation for new business opportunities
in 2018 including what could be the world&#146;s first nicotine edibles for the
smokeless tobacco industry, or improved new products for NSAID-derived pain
management, as well as in the rapidly growing cannabis market.&#148;</P>
<P align=justify>Lexaria&#146;s patented DehydraTECH&#153; technology is focused on
improved delivery<I> </I>methodologies of many commonly used API substances. As
such, it provides an additional layer of effectiveness that is designed to harmonize with the intellectual property of
third parties. Both patented and generic API substances can utilize Lexaria&#146;s
patented technology. Lexaria&#146;s long term strategy is to partner with the world&#146;s
leading firms as they deliver best-of-class products to their existing large
consumer groups.</P>
<HR style="PAGE-BREAK-AFTER: always" align=center width="100%" color=black
noShade SIZE=5>
<A name=page_2></A>
<P align=justify>Lexaria is presently investigating and will continue to pursue
additional technologies that could deliver value to its growing portfolio of
patented technologies. </P>
<P align=justify><B>About Lexaria <BR></B>Lexaria Bioscience Corp. has developed
and out-licenses its disruptive delivery technology that promotes healthier
ingestion methods, lower overall dosing and higher effectiveness of lipophilic
active molecules. Lexaria has multiple patents pending in over 40 countries
around the world and has patents granted in the USA and in Australia for
utilization of its DehydraTECH<SUP>TM </SUP>delivery technology. Lexaria&#146;s
technology provides increases in intestinal absorption rates; more rapid
delivery to the bloodstream; and important taste-masking benefits, for orally
administered bioactive molecules including cannabinoids, vitamins, non-steroidal
anti-inflammatory drugs (NSAIDs), nicotine and other molecules. <BR><U><FONT
color=#0000ff>www.lexariabioscience.com </FONT></U></P><IMG
src="facetwit.jpg"
border=0> <BR>
<P align=justify>For regular updates, connect with Lexaria on Twitter (<U><FONT
color=#0000ff>https://twitter.com/lexariacorp</FONT>) </U>and on Facebook
<U><FONT color=#0000ff>http://tinyurl.com/y8vzcaam </FONT></U></P>
<P align=justify>FOR FURTHER INFORMATION PLEASE CONTACT:<BR>Lexaria Bioscience
Corp.<BR>Alex Blanchard, Communications Manager <BR>(778) 796-1897 <BR>Or
<BR>NetworkNewsWire (NNW) <BR><U><FONT color=#0000ff>www.NetworkNewsWire.com
</FONT></U><BR>FORWARD-LOOKING STATEMENTS <BR></P>
<P align=justify>This release includes forward-looking statements. Statements
which are not historical facts are forward-looking statements. The Company makes
forward-looking public statements concerning its expected future financial
position, results of operations, cash flows, financing plans, business strategy,
products and services, competitive positions, growth opportunities, plans and
objectives of management for future operations, including statements that
include words such as "anticipate," "if," "believe," "plan," "estimate,"
"expect," "intend," "may," "could," "should," "will," and other similar
expressions are forward-looking statements, including but not limited to: that
any additional patent protection will be realized or that patent achievements
will deliver material results. Such forward-looking statements are estimates
reflecting the Company's best judgment based upon current information and
involve a number of risks and uncertainties, and there can be no assurance that
other factors will not affect the accuracy of such forward-looking statements.
Factors which could cause actual results to differ materially from those
estimated by the Company include, but are not limited to, government regulation,
managing and maintaining growth, the effect of adverse publicity, litigation,
competition, scientific discovery, the patent application and approval process
and other factors which may be identified from time to time in the Company's
public announcements and filings. There is no assurance that existing capital is
sufficient for the Company's needs or that it will be able to raise additional
capital. There is no assurance the Company will be capable of developing,
marketing, licensing, or selling edible products containing nicotine or any
other active ingredient. There is no assurance that any planned corporate
activity, scientific research or study, business venture, technology licensing
pursuit, patent application or allowance, consumer study, or any initiative will
be pursued, or if pursued, will be successful. There is no assurance that any of
Lexaria&#146;s postulated uses, benefits, or advantages for the patented and
patent-pending technology will in fact be realized in any manner or in any part.
No statement herein has been evaluated by the Food and Drug Administration
(FDA). Lexaria-associated products are not intended to diagnose, treat, cure or
prevent any disease.</P>
<P align=justify><I>The CSE has not reviewed and does not accept responsibility
for the adequacy or accuracy of this release. </I></P>
<HR align=center width="100%" color=black noShade SIZE=5>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>facetwit.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 facetwit.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!# ! +# X,"A .#0X2$1 3&"@:&!86
M&#$C)1TH.C,]/#DS.#= 2%Q.0$1713<X4&U15U]B9VAG/DUQ>7!D>%QE9V/_
MVP!# 1$2$A@5&"\:&B]C0CA"8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V-C
M8V-C8V-C8V-C8V-C8V-C8V-C8V-C8V/_P  1"  R &X# 2(  A$! Q$!_\0
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M<.XPH/85/9:);6K!VS+(.A;H/PK3K&OB5)<L3IPN"=.7//<****XST@HHHH
:**** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
